SEC Filings | Nurix Therapeutics, Inc.

Corporate Profile

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Filing date	Description	Form	View
September 18, 2015		D	0001549595-15-000002.pdf 0001549595-15-000002.rtf View HTML
March 26, 2020		D	0001549595-20-000001.pdf 0001549595-20-000001.rtf 0001549595-20-000001.xls View HTML
March 28, 2013		D/A	0001549595-13-000001.pdf 0001549595-13-000001.rtf View HTML
March 25, 2021	Official notification to shareholders of matters to be brought to a vote ("Proxy")	DEF 14A	0001193125-21-093256.pdf 0001193125-21-093256.rtf 0001193125-21-093256.xls View HTML
March 25, 2022	Official notification to shareholders of matters to be brought to a vote ("Proxy")	DEF 14A	0001193125-22-084520.pdf 0001193125-22-084520.rtf 0001193125-22-084520.xls View HTML
March 24, 2023	Official notification to shareholders of matters to be brought to a vote ("Proxy")	DEF 14A	0001140361-23-013573.pdf 0001140361-23-013573.rtf 0001140361-23-013573.xls View HTML
March 27, 2024	Official notification to shareholders of matters to be brought to a vote ("Proxy")	DEF 14A	0001140361-24-015447.pdf 0001140361-24-015447.rtf 0001140361-24-015447.xls View HTML
March 25, 2021	Additional proxy soliciting materials - definitive	DEFA14A	0001193125-21-093271.pdf 0001193125-21-093271.rtf 0001193125-21-093271.xls View HTML
March 25, 2022	Additional proxy soliciting materials - definitive	DEFA14A	0001193125-22-084525.pdf 0001193125-22-084525.rtf View HTML
March 24, 2023	Additional proxy soliciting materials - definitive	DEFA14A	0001140361-23-013574.pdf 0001140361-23-013574.rtf 0001140361-23-013574.xls View HTML

Monday, May 20, 2024, at 9:30 AM Pacific Time

Nurix’s 2024 Annual Meeting of Stockholders will be held on Monday, May 20, 2024.

Stockholders of record of Nurix common stock as of the close of business on March 21, 2024, are entitled to vote at the meeting. The live webcast of the meeting will be accessible by visiting www.virtualshareholdermeeting.com/NRIX2024.

Copies of the CEO Letter, Proxy Statement and Annual Report to Shareholders for the 2024 Annual Meeting of Stockholders are available on the “Events and Presentations” page within the “Investors” section of our website.

Investors

Corporate Profile

2024

2023

2022

2021

2020

Monday, May 20, 2024, at 9:30 AM Pacific Time